Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N +-glucuronide in plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 895-896, Issue , 2012, Pages 169-173

  Sparidans, Rolf W ^a   Durmus, Selvi ^b   Xu, Ning ^b   Schinkel, Alfred H ^b   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cediranib; Cediranib N + glucuronide; Human plasma; LC MS MS; Mouse plasma; VEGF inhibitor

Indexed keywords

CEDIRANIB; GLUCURONIDES; HUMAN PLASMAS; LC-MS/MS; MOUSE PLASMA; VEGF INHIBITOR;

ACETONITRILE; ELECTROSPRAY IONIZATION; FORMIC ACID; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; METABOLITES; METHANOL; PLASMA (HUMAN); SILICA; SOLVENT EXTRACTION;

BIOMOLECULES;

ACETONITRILE; CEDIRANIB; ERLOTINIB; FORMIC ACID; GLUCURONIDE; METHANOL; OCTADECYLSILICON DIOXIDE; SILICON DIOXIDE; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; HUMAN; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMA; POSITIVE ION ELECTROSPRAY; PRECIPITATION; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

ANIMALS; BENZAMIDES; CHROMATOGRAPHY, LIQUID; GLUCURONIDES; HUMANS; LINEAR MODELS; MICE; PYRIMIDINES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84860127805     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.03.020     Document Type: Article

References (12)

1. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., Smith N.R., James N.H., Dukes M., Curwen J.O., et al. Cancer Res. 2005, 65:4389.
2. US National Institutes of Health, <> (accessed 15.09.11). http://clinicaltrials.gov/ct2/search.
3. Schulz-Utermoehl T., Spear M., Pollard C.R., Pattison C., Rollison H., Sarda S., Ward M., Bushby N., Jordan A., Harrison M. Drug Metab. Dispos. 2010, 38:1688.
4. Lenz E.M., Spear M., Drake C., Pollard C.R., Ward M., Schulz-Utermoehl T., Harrison M. J. Pharm. Biomed. Anal. 2010, 53:526.
5. Mitchell C.L., O'Connor J.P., Roberts C., Watson Y., Jackson A., Cheung S., Evans J., Spicer J., Harris A., Kelly C., et al. Cancer Chemother. Pharmacol. 2011, 68:631.
6. Wang T., Oberoi R.K., Elmquist W.F. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:3812.
7. Brandon E.F., Sparidans R.W., Guijt K.J., Lowenthal S., Meijerman I., Beijnen J.H., Schellens J.H. Invest. New Drugs 2006, 24:3.
8. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, <>, 2001 (accessed 26.04.11). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm.
9. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Pharm. Res. 2000, 17:1551.
10. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Pharm. Res. 2007, 24:1962.
11. Sparidans R.W., Iusuf D., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:4090.
12. European Medicines Agency, <>, 2009 (accessed 26.04.11). http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf.